Side Effects After Direct-acting Antiviral Treatment
Completed
- Conditions
- Chronic Hepatitis c
- Registration Number
- NCT03346941
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
The objective of this study was to assess the incidence of side effects after direct-acting antiviral therapy in patients with chronic hepatitis C virus infection.
- Detailed Description
Direct-acting antiviral (DAA)-based treatments are today very effective The objective of this study was to assess the incidence of side effects after DAA therapy in patients with chronic hepatitis C virus infection.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 95
Inclusion Criteria
- 18 years of age or older
- Hepatitis C virus infection
- Treatment by direct-acting antiviral combination
Exclusion Criteria
- HIV coinfection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of side effects Within treatment duration, i.e. 8, 12 or 24 weeks after treatment initiation Incidence of side effects occurring during treatment duration. Treatment duration may be of 8 weeks, 12 weeks or 24 weeks depending on treatment combination.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Croix-Rousse Hospital, Hospices Civils de Lyon
🇫🇷Lyon, France